Evidence map›Paper›PMID 30972664›Full record

ArticleDrug delivery and translational research2019

RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells.

Bo Lou, Kate Connor, Kieron Sweeney, Ian S Miller, Alice O'Farrell, Eduardo Ruiz-Hernandez, David M Murray, Garry P Duffy, Alan Wolfe, Enrico Mastrobattista and 2 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Bo LouDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands.
Kate ConnorDepartment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, York Street, Dublin 2, Ireland.
Kieron SweeneyDepartment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, York Street, Dublin 2, Ireland.
Ian S MillerDepartment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, York Street, Dublin 2, Ireland.
Alice O'FarrellDepartment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, York Street, Dublin 2, Ireland.
Eduardo Ruiz-HernandezSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.
David M MurrayDepartment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, York Street, Dublin 2, Ireland.
Garry P DuffyAnatomy, School of Medicine, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland.
Alan WolfeUCD School of Veterinary Medicine, Belfield, Dublin, Ireland.
Enrico MastrobattistaDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands.
Annette T ByrneDepartment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, York Street, Dublin 2, Ireland.
Wim E HenninkDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands. W.E.Hennink@uu.nl.
Royal College of Surgeons in Ireland · IEUtrecht University · NLBeaumont Hospital · IEOllscoil na Gaillimhe – University of Galway · IETrinity College Dublin · IEUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of an effective and safe treatment for glioblastoma (GBM) represents a significant challenge in oncology today. Downregulation of key mediators of cell signal transduction by RNA interference is considered a promising treatment strategy but requires efficient, intracellular delivery of siRNA into GBM tumor cells. Here, we describe novel polymeric siRNA nanocarriers functionalized with cRGD peptide that mediates targeted and efficient reporter gene silencing in U87R invasive human GBM cells. The polymer was synthesized via RAFT copolymerization of N-(2-hydroxypropyl)-methacrylamide (HPMA) and N-acryloxysuccinimide (NAS), followed by post-polymerization modification with cholesterol for stabilization, cationic amines for siRNA complexation, and azides for copper-free click chemistry. The novel resultant cationic polymer harboring a terminal cholesterol group, self-assembled with siRNA to yield nanosized polyplexes (~ 40 nm) with good colloidal stability at physiological ionic strength. Post-modification of the preformed polyplexes with PEG-cRGD end-functionalized with bicyclo[6.1.0]nonyne (BCN) group resulted in enhanced cell uptake and increased luciferase gene silencing in U87R cells, compared to polyplexes lacking cRGD-targeting groups.

Indexed as

Brain NeoplasmsCell Line, TumorCell SurvivalCholesterolGlioblastomaHumansLuciferasesNanoparticlesPeptides, CyclicPolymersRNA, Small InterferingCholesterolcyclic arginine-glycine-aspartic acid peptideLuciferasesPeptides, CyclicPolymersRNA, Small InterferingCancer targetingCholesterol modificationcRGD peptideGlioblastomasiRNA delivery

Identifiers

PMID30972664
OpenAlexW2940142482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.